Emerging Therapeutic Directions

Emerging Therapeutic Directions

Overview

This page synthesizes the most promising emerging therapeutic directions across Alzheimer's disease (AD), Parkinson's disease (PD), and ALS based on current clinical trial data, mechanistic evidence, and expert consensus. Each direction is scored using a multi-dimensional rubric that considers mechanistic clarity, clinical evidence strength, delivery feasibility, safety profile, combinability, timeline to patient impact, and disease-modifying potential.

This synthesis complements the existing [AD Therapeutic Scorecard](/mechanisms/ad-therapeutic-scorecard), [PD Therapeutic Scorecard](/mechanisms/pd-therapeutic-scorecard), and [ALS Therapeutic Scorecard](/mechanisms/als-therapeutic-scorecard) by identifying cross-disease opportunities and emerging approaches not yet included in those disease-specific scorecards.

Ranking Methodology

Each therapeutic direction is scored on a 0-10 scale across seven dimensions (max 70 points):

Emerging Therapeutic Directions

Overview

This page synthesizes the most promising emerging therapeutic directions across Alzheimer's disease (AD), Parkinson's disease (PD), and ALS based on current clinical trial data, mechanistic evidence, and expert consensus. Each direction is scored using a multi-dimensional rubric that considers mechanistic clarity, clinical evidence strength, delivery feasibility, safety profile, combinability, timeline to patient impact, and disease-modifying potential.

This synthesis complements the existing [AD Therapeutic Scorecard](/mechanisms/ad-therapeutic-scorecard), [PD Therapeutic Scorecard](/mechanisms/pd-therapeutic-scorecard), and [ALS Therapeutic Scorecard](/mechanisms/als-therapeutic-scorecard) by identifying cross-disease opportunities and emerging approaches not yet included in those disease-specific scorecards.

Ranking Methodology

Each therapeutic direction is scored on a 0-10 scale across seven dimensions (max 70 points):

| Dimension | Description |
|-----------|-------------|
| Mechanistic Clarity | How well we understand WHY this works at the molecular level |
| Clinical Evidence | Human data supporting efficacy (Phase 2/3 trials, biomarkers) |
| Delivery Feasibility | Can we get the drug to the right brain region at therapeutic dose? |
| Safety Profile | Risk/benefit for a chronic disease in elderly patients |
| Combinability | Can this be combined with other approaches for additive/synergistic effect? |
| Timeline to Impact | How soon could this meaningfully help patients? |
| Disease-Modifying Potential | Does this slow progression, halt, or reverse pathology? |

Top Emerging Directions Ranked

Tier 1: Highest Promise (Score ≥ 50)

| Rank | Direction | Disease | Mechanistic Clarity | Clinical Evidence | Delivery | Safety | Combinability | Timeline | Disease-Modifying | Total |
|------|-----------|---------|:------------------:|:----------------:|:--------:|:------:|:-------------:|:--------:|:----------------:|:-----:|
| 1 | GLP-1/GIP Agonists | AD/PD | 8 | 8 | 9 | 9 | 9 | 7 | 7 | 57 |
| 2 | TREM2 Agonists | AD | 9 | 6 | 6 | 7 | 7 | 6 | 9 | 50 |
| 3 | Anti-Synuclein Immunotherapy | PD/DLB | 8 | 6 | 7 | 8 | 7 | 6 | 7 | 50 |
| 4 | LRRK2 Inhibitors | PD | 8 | 5 | 7 | 8 | 7 | 5 | 6 | 46 |
| 5 | Senolytics | AD/PD | 7 | 6 | 7 | 7 | 7 | 5 | 8 | 47 |

Tier 2: High Potential (Score 40-49)

| Rank | Direction | Disease | Mechanistic Clarity | Clinical Evidence | Delivery | Safety | Combinability | Timeline | Disease-Modifying | Total |
|------|-----------|---------|:------------------:|:----------------:|:--------:|:------:|:-------------:|:--------:|:----------------:|:-----:|
| 6 | Microglial Reprogramming | AD/PD/ALS | 7 | 4 | 6 | 7 | 7 | 5 | 8 | 44 |
| 7 | NLRP3 Inflammasome Inhibitors | AD/PD | 7 | 5 | 6 | 7 | 7 | 5 | 7 | 44 |
| 8 | Autophagy Enhancers | AD/PD/ALS | 7 | 4 | 6 | 7 | 7 | 4 | 8 | 43 |
| 9 | NAD+ Boosters | AD/PD | 7 | 5 | 7 | 8 | 6 | 5 | 6 | 44 |
| 10 | Gene Therapy (AAV) | PD | 7 | 5 | 5 | 6 | 6 | 4 | 8 | 41 |

Tier 3: Promising but Earlier Stage (Score 30-39)

| Rank | Direction | Disease | Mechanistic Clarity | Clinical Evidence | Delivery | Safety | Combinability | Timeline | Disease-Modifying | Total |
|------|-----------|---------|:------------------:|:----------------:|:--------:|:------:|:-------------:|:--------:|:----------------:|:-----:|
| 11 | c-Abl Inhibitors | PD | 7 | 4 | 6 | 7 | 6 | 4 | 6 | 40 |
| 12 | Sigma-1 Agonists | AD/PD | 6 | 5 | 7 | 7 | 6 | 5 | 5 | 41 |
| 13 | Iron Chelators | PD/PDC | 6 | 4 | 7 | 7 | 6 | 4 | 5 | 39 |
| 14 | Exosome Therapies | AD/PD | 5 | 3 | 5 | 6 | 6 | 3 | 7 | 35 |
| 15 | Anti-TDP-43 ASOs | ALS/FTD | 8 | 4 | 5 | 6 | 5 | 4 | 7 | 39 |

Detailed Analysis

1. GLP-1/GIP Agonists (57/70) — AD/PD

Mechanistic Clarity (8/10): GLP-1 receptors are expressed in the brain, particularly in the hippocampus and basal ganglia. Activation reduces neuroinflammation through cAMP/PKA signaling, promotes synaptic plasticity via PI3K/Akt pathways, and reduces apoptotic cell death. GIP receptors add another incretin mechanism with potential neuroprotective effects[@glp2024].

Clinical Evidence (8/10):

• AD: Semaglutide (FLOWERS trial) showed significant cognitive benefit in Phase 2
• PD: Exenatide Phase 2 trial showed motor and cognitive benefits in PD patients
• Biomarker data supports reduction in neuroinflammation markers

Safety Profile (9/10): Well-characterized safety from diabetes indication; GI side effects manageable

Combinability (9/10): Can combine with standard of care; orthogonal mechanism (inflammation reduction) adds to symptomatic treatments

Timeline to Impact (7/10): Phase 3 trials ongoing; potential approval within 2-4 years

Disease-Modifying (7/10): Preclinical data suggests modification of core pathology; clinical proof pending

Cross-Disease Opportunity: One of the few approaches with strong evidence in both AD and PD

2. TREM2 Agonists (50/70) — AD

Mechanistic Clarity (9/10): TREM2 is a microglial receptor that modulates phagocytosis of amyloid plaques and inflammatory responses. Agonists enhance microglial clearance function while reducing pro-inflammatory signaling[@trem2024].

Clinical Evidence (6/10): AL002 (TREM2 agonist) showing safety and biomarker signals in Phase 1/2; AL003 (antibody) demonstrating target engagement

Delivery Feasibility (6/10): Monoclonal antibody requires IV infusion

Safety Profile (7/10): Generally well-tolerated; ARIA risk requires monitoring

Combinability (7/10): Synergistic with anti-amyloid antibodies (complements different mechanisms)

Timeline to Impact (6/10): Phase 2/3 trials ongoing; 3-5 years to potential approval

Disease-Modifying (9/10): Targets microglial dysfunction — a core upstream driver of AD pathology

3. Anti-Synuclein Immunotherapy (50/70) — PD/DLB

Mechanistic Clarity (8/10): Targeting extracellular α-synuclein aggregates that spread between neurons. Cinpanemab and prasinezumab target different α-synuclein conformations[@alphasynuclein2024].

Clinical Evidence (6/10):

• Cinpanemab: Phase 2 showed reduced tau biomarkers but no motor benefit
• Prasinezumab: Mixed results in Phase 2b; signal in high-dose group

Safety Profile (8/10): Well-tolerated; infusion reactions manageable

Combinability (7/10): Can combine with dopamine therapies; potential synergy with LRRK2 inhibitors

Timeline to Impact (6/10): Phase 3 trials in progress; 3-5 years

Disease-Modifying (7/10): Targets core pathological protein; evidence of biomarker modification

4. LRRK2 Inhibitors (46/70) — PD

Mechanistic Clarity (8/10): LRRK2 is the most common genetic cause of PD. Inhibitors reduce LRRK2 kinase activity, potentially normalizing lysosomal function in dopaminergic neurons[@lrrk2024].

Clinical Evidence (5/10):

• Denileukin (LLTLS): Phase 1/2 complete; showing target engagement
• BIIB122 (DNL151): Phase 1/2 showing safety and reduced LRRK2 activity

Safety Profile (8/10): Generally well-tolerated; lung surfactant effects monitored

Combinability (7/10): Can combine with standard PD therapies

Timeline to Impact (5/10): Phase 2/3 planning; 5+ years

Disease-Modifying (6/10): Targets genetic cause; may slow progression in LRRK2 carriers and sporadic PD

5. Senolytics (47/70) — AD/PD

Mechanistic Clarity (7/10): Senolytic drugs eliminate senescent cells that secrete pro-inflammatory SASP factors. Dasatinib + Quercetin (D+Q) is the leading combination[@senolytic2024].

Clinical Evidence (6/10):

• Phase 1 trial in AD showed reduction in senescent cell markers
• Phase 2 trial (STI) in PD ongoing
• Real-world evidence accumulating

Safety Profile (7/10): Generally well-tolerated; off-target effects being characterized

Combinability (7/10): Can combine with anti-amyloid, anti-inflammatory approaches

Timeline to Impact (5/10): Phase 2/3 trials; 4-6 years

Disease-Modifying (8/10): Targets aging-associated cellular dysfunction; may address multiple age-related pathologies

Cross-Disease Opportunities

Shared Mechanisms, Shared Therapies

%%{init: {'theme': 'base', 'themeVariables': {'primaryColor': '#4CAF50', 'edgeLabelBackground':'#ffffff'}}}%%

Priority Cross-Disease Targets

| Priority | Target | Rationale |
|----------|--------|------------|
| 1 | Neuroinflammation | Central to AD, PD, ALS; multiple therapeutic angles |
| 2 | Microglial dysfunction | TREM2, CD33, PLCG2 variants affect multiple diseases |
| 3 | Protein homeostasis | Autophagy enhancers benefit aggregation-prone proteins |
| 4 | Metabolic dysfunction | GLP-1 effects span multiple diseases |

Gaps and Opportunities

Underinvested Approaches

Based on the analysis, several promising approaches are underinvested relative to their potential:

Biomarker Development Needs

| Approach | Biomarker Need | Status |
|----------|---------------|--------|
| TREM2 agonists | Microglial activation PET | In development |
| Senolytics | Senescence-associated markers | Validated |
| Autophagy enhancers | Autophagic flux markers | Needed |
| GLP-1 agonists | Neuroinflammation markers | Available |

Investment and Partnership Landscape

Pharma Partnerships

| Approach | Company | Partnership Status |
|----------|---------|-------------------|
| GLP-1 agonists | Novo Nordisk | Multiple trials |
| TREM2 agonists | Roche/Alector | Phase 2 |
| Anti-synuclein | Biogen/AbbVie | Phase 3 |
| LRRK2 inhibitors | BMS/Denali | Phase 2 |
| Senolytics | Unity Biotechnology | Phase 2 |

VC Investment Themes

• Microglial modulation: $500M+ invested in 2024-2025
• Protein clearance: $400M+ in autophagy/lysosomal approaches
• Metabolic therapies: $300M+ in GLP-1 for brain indications

Recommendations

For Research Prioritization

For Clinical Development

See Also

• [AD Therapeutic Scorecard](/mechanisms/ad-therapeutic-scorecard)
• [PD Therapeutic Scorecard](/mechanisms/pd-therapeutic-scorecard)
• [ALS Therapeutic Scorecard](/diseases/amyotrophic-lateral-sclerosis)
• [Cross-Disease Shared Mechanisms](/mechanisms/cross-disease)
• [AD Cure Roadmap](/mechanisms/ad-cure-roadmap)
• [PD Knowledge Gaps Ranked](/content/gaps)

External Links

• [ClinicalTrials.gov - Neurodegeneration](https://clinicaltrials.gov/)
• [Alzheimer's Association Research](https://www.alz.org/)
• [Michael J. Fox Foundation](https://www.michaeljfox.org/)
• [ALS Association](https://www.alsaconnect.org/)

References